Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 9/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.54 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.54 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.42 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.42 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.42 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.42 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4739317 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL2761798 | 0.99 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL902225 | 0.99 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL4967524 | 0.99 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL902452 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL8028845 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL8028820 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL4111320 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL4627006 | 0.81 | OPRM1 (0.39) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL4632472 | 0.81 | CHRNB2 (0.43) | SLC6A2SLC6A4SLC6A3LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125698-A1 | DEUTERATED VENLAFAXINES AND 0-DESMETHYLVENLAFAXINES WITH SEROTONINERGIC AND /OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008140859-A1 | DEUTERATED VENLAFAXINES AND 0-DESMETYLVENLAFAXINES WITH SEROTONINERGIC AND / OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2015063791-A1 | NOVEL PROCESS FOR TOTAL SYNTHESIS OF VENLAFAXINE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-05-07 | — | — | WO | disclosed |
| WO-2010046808-A2 | A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | disclosed |
| EP-2081885-A2 | IMPROVED PROCESSES FOR PREPARING VENLAFAXINE BASE AND SALTS THEREOF | Medichem, S.A. (ES) | 2009-07-29 | — | — | EP | disclosed |
| EP-1957470-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | Wyeth (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008038146-A2 | IMPROVED PROCESSES FOR PREPARING VANLAFAXINE BASE AND SALTS THEREOF | MEDICHEM, S.A. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1684689-A4 | EXTENDED RELEASE VENLAFAXINE FORMULATION | ANDRX PHARMACEUTICALS LLC (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1824815-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824815-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007047972-A3 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMA (IL) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007067501-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | WYETH (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129562-A1 | Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129562-A1 | Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129562-A1 | Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007047972-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047972-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-26 | — | — | WO | disclosed |
| EP-1684689-A2 | EXTENDED RELEASE VENLAFAXINE FORMULATION | ANDRX Pharmaceuticals LLC. (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005048923-A2 | EXTENDED RELEASE VENLAFAXINE FORMULATION | ANDRX PHARMACEUTICALS, LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2003050074-A1 | MANUFACTURE OF VENLAFAXINE HYDROCHLORIDE AND CRYSTALLINE POLYMORPHS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129562-A1 | Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride | HTR1F, CYP2F1, HTR1A | SLC6A2 49/4885SLC6A4 68/4885SLC6A3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.